Satraplatin: Difference between revisions
m Protected "Satraplatin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 12: | Line 12: | ||
{{reflist}} | {{reflist}} | ||
[[Category:Chemotherapeutic agents]] | [[Category:Chemotherapeutic agents]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 15:53, 20 August 2012
WikiDoc Resources for Satraplatin |
Articles |
---|
Most recent articles on Satraplatin Most cited articles on Satraplatin |
Media |
Powerpoint slides on Satraplatin |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Satraplatin at Clinical Trials.gov Clinical Trials on Satraplatin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Satraplatin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Satraplatin Discussion groups on Satraplatin Patient Handouts on Satraplatin Directions to Hospitals Treating Satraplatin Risk calculators and risk factors for Satraplatin
|
Healthcare Provider Resources |
Causes & Risk Factors for Satraplatin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
The drug is taken by mouth. It is made available in the United States jointly by Spectrum Pharmaceuticals and GPCbiotech under the name Spera.
The drug has also been used in the treatment of lung and ovarian cancers. The mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing. [1]